The Perseus Foundation

05/15/2024

Warmest congratulations to PetCure Oncology!

05/15/2024

Friends, Don't miss this enlightening episode of the Veterinary Cancer Pioneers Podcast! 🎙️ Dr. Rachel Venable hosts the brilliant Dr. Chand Khanna, a luminary in veterinary and human oncology. Dive into the world of "communicative medicine" as Dr. Khanna shares his expertise garnered from a distinguished career. 🐾 Exciting updates on groundbreaking research at Ethos Discovery await, including insights from a nationwide clinical trial challenging the norms in splenic hemangiosarcoma treatment. 📈 Tune in to explore the potential revolution in canine cancer therapy!

In this insightful episode of the Veterinary Cancer Pioneers Podcast, Dr. Rachel Venable welcomes the esteemed Dr. Chand Khanna, founder and board chair of E...

03/13/2024

Each year, March 13th is dedicated to National K9 Veterans Day — a day for recognizing and honoring the service and sacrifices of military and working dogs. It marks the official birthday of the United States K9 Corps, which was established back in 1942 for the first military dogs who served. 🐾❤️🐾

Through the MiliDog Fund, The Perseus Foundation helps defray the cost of cancer for our hero dogs.

Bellingham Veterinary in Bellingham, Washington provides free care for Retired Military Dogs and Retired Contract Dogs.

Our heartfelt gratitude for your incredible generosity, kindness and caring.

Bak's Legacy is the financial assistance fund within the MiliDog Program.

03/11/2024

ACI Biosciences is currently enrolling dogs in a fully-funded clinical trial to assess an innovative, orally administered treatment for canine lymphoma, the first of its kind. Take this short survey to connect with a study team member (https://lnkd.in/euEVDx5Q) and learn more at https://lnkd.in/g6Yb3vh
🦮🐾

03/08/2024

World, please help us by sharing. It promises to be a magical day and the sweetest of ways to honor Blaze!

Thank you 💚🐾❤️

We are just over one month away from the inaugural Blaze's Walk and are so excited to be partnering with ! Come out to Seneca Creek State Park on Sunday, April 7th, to help us honor Blaze, raise funds for the Perseus Foundation to help other canine lymphoma patients, and maybe even adopt a new furry friend!

Register here: https://www.wetravel.com/trips/blaze-s-walk-fundraiser-for-canine-lymphoma-blaze-adventure-tours-centennial-lake-maryland-14492389

This event is so much more than just a walk. There will be demos from dog trainers and veterinary experts, games, and more. Registration includes a t-shirt, lunch from , beer, and other swag. Don't forget to purchase some raffle tickets for the chance to win some super cool prizes! A photography session, dog training lesson, Baltimore or Annapolis harbor cruise tickets, and wine tastings, just to name a few.

We could not do this without our amazing sponsors. Thank you to , Apex Executive Search (.550), Zeynap & Otto,

02/26/2024

Clinical trials are research studies that help Flint Animal Cancer Center at CSU VTH improve diagnostic tests and treatment options. Our clinical trials program enrolls client-owned pets to evaluate the effectiveness of new drugs, find novel uses of old drugs, or investigate new approaches to surgery and/or radiation therapy to treat cancer.

Many of the standard treatments used today are the result of clinical trials. We learn valuable information from every patient, and we use this information to improve their care as well as the care of future patients, both pets and people.

02/16/2024

🐾 Neo's Journey: From Lymphoma Diagnosis to Cancer Survivor 🐾

We're proud to spotlight Neo, this week's Oncology Pet at Purdue Veterinary Medicine. Completing a rigorous 6-month CHOP chemotherapy protocol, Neo's resilience shines through. His family chose Purdue for its exceptional care, hoping to restore his vibrant spirit - a goal we've proudly achieved together.

Neo's story is a testament to love, determination, and the advanced oncological care available at Purdue. Let's celebrate Neo's health and happiness!

Meet Neo’s team at https://lnkd.in/gkpzwMi

Purdue University

02/16/2024

Hi Friends 💙💚🤍

Let’s Celebrate and Honor Blaze by spreading the news!

What is Blaze's Walk Blaze's walk is both a fundraiser and a celebration of life in honor of Blaze and all the other dogs who have been lost to canine lymphoma. Our goal is to raise money for the Perseus Foundation in order to help provide costly life-saving treatment to dogs for bone marrow transpl...

02/15/2024

So very happy to hear about Blue Pearl’s Initiative 💙🎈💙

BluePearl announces the launch of its charitable arm, BluePearl Cares, a nonprofit organization with a mission of making emergency and specialty veterinary care accessible for all.

02/15/2024

🐾💙🎉Purdue University and its cross-disciplinary team is making strides in cancer research with a novel application of Doppler ultrasound to identify chemoresistance. This significant breakthrough could establish a new standard for personalized medicine, enhancing the precision of cancer treatment.

Learn how this technique, moving from phase-2 canine to human trials, demonstrates the potential of mechanical motion measurements in predicting chemotherapeutic outcomes: https://purdue.vet/3uwkMzF

Purdue University AVMA (American Veterinary Medical Association) American Animal Hospital Association American Animal Hospital Association Purdue Institute for Cancer Research

02/14/2024

PetCure Oncology their approach to combating cancer in pets is rooted in the pursuit of a cure. They understand that the journey of cancer treatment encompasses a range of outcomes and results.

Factors Influencing Prognosis:

The effectiveness of SRS in treating cancer depends on multiple factors including:
Cancer type
Location
Stage

Their team assesses these elements to provide a tailored treatment plan, maximizing the potential for a positive outcome: shrinking tumors, slowing tumor growth or even achieving remission in some cases.

Regardless of the prognosis, Pet Cure Oncology’s focus remains steadfast on enhancing the quality of life for each and every pet. By combining advanced treatment with compassionate care, we aim to extend the lives of our furry patients while ensuring their comfort and well-being.

How Much Does SRS/SRT Cost?

The cost of treatment can vary significantly depending on whether the treatment is for palliative, conventional, or stereotactic radiation therapy (SRS/SRT).
• Palliative Radiation Therapy starts at about $3,500
• Conventional Radiation (CFRT) ranges from $7,500 - $13,500
• SRS/SRT protocols range from $9,000 - $12,000.

📱☎️📞PetCure Oncology | (833) VET-HERO |

02/13/2024

Exciting News.

🐾❤️🐾 ACI Biosciences is currently enrolling dogs in a fully-funded clinical trial to assess an innovative, orally administered treatment for canine lymphoma, the first of its kind. Take this short survey to connect with a study team member (https://lnkd.in/euEVDx5Q) and learn more at https://lnkd.in/g6Yb3vhM

02/13/2024

Cats get cancer, too! Unfortunately, when they do, it’s often very serious by the time of diagnosis. CSU is on a mission to improve outcomes for feline cancer. They have two new cat-specific clinical trials open. Join the fight against feline cancer – please help CSU spread the word!

Find open trials here: https://buff.ly/3GSNxbX

02/07/2024

https://eliasanimalhealth.com/blog/can-we-treat-cancer-without-chemotherapy/

Cancer is the leading cause of death in dogs, and in humans it is second only to heart disease. For decades, chemotherapy has been the only option and a necessary evil to treat cancer. Most of us know someone who has gone through chemo, and

02/07/2024

Just In🐾

New Immunotherapy Trial for Lymphoma from ELIAS Animal Health

Having focused on osteosarcoma in their just-completed trial, ELIAS Animal Health has announced a new trial for dogs with lymphoma.

ELIAS makes “personalized” vaccines for dog cancer that leverage your dog’s immune system to fight cancer. It’s a fascinating idea; you can learn more about it in this episode of DOG CANCER ANSWERS featuring CEO Tammie Wahaus.

The new trial, which will only have one location to start, will look at using their immunotherapy in combination with the VCAA chemo protocol. (That’s L-asparaginase, vincristine, cyclophosphamide, and doxorubicin.) Once dogs have received eight sessions of chemotherapy, they will be administered immunotherapy.

Then, they’ll be monitored for 18 months, after which time ELIAS will be able to compare them to a similar group of dogs (using historical data) who received only chemotherapy.

Will the immunotherapy extend remission? Survival times? They’ll know more in a couple of years!

02/02/2024

Flint Animal Cancer Center at CSU . ❤️felt thanks for such awesome care! loves you Chloe❤️

Awesome News! Chloe was treated with radiation therapy for a histiocytic sarcoma tumor back in 2016. At the time, we weren’t sure how successful the treatment would be.

Chloe’s owners recently checked in. She’s now 15 and still living life to the fullest. She’s aging but has shown no signs of cancer returning.

She is the cutest and happiest dog and we’re so grateful to have received this update.

01/24/2024

From the Flint Animal Cancer Center at CSU VTH.

Last month the first veterinary patient received an nfusion of CAR T cells as part of a clinical trial for treatment of bone cancer that has spread to the lungs.

CAR T cells are a form of immunotherapy that is used in people for a variety of cancer types. We are very excited to be able to use this in our patients and are hopeful that this will be an effective treatment for pets as well! Go, Gucci, go!

Thank you so much for your amazing contributions in treating our beloved animal buddies!❤️

01/24/2024

Great opportunity to enlist a Veterinary Oncologist to wirk with your primary veterinarian!

https://petcancercareconsulting.com/about-us/

01/20/2024

ACI Biosciences is currently enrolling dogs in a fully-funded clinical trial to assess an innovative, orally administered treatment for canine lymphoma, the first of its kind!

01/15/2024

Purdue Veterinary Medicine is conducting a landmark clinical trial for dogs diagnosed with brain tumors, specifically meningioma or glioma. This trial not only aims to enhance treatment protocols but also offers a substantial financial incentive by providing free radiation treatment post-surgery, valued at over $7,000.

We invite you to visit https://purdue.vet/ctr-canine to explore the eligibility criteria and learn more about how your dog can contribute to this pioneering study.

American Animal Hospital Association (AAHA) Purdue Institute for Cancer Research Purdue University

01/03/2024

https://www.dvm360.com/view/new-study-shows-blood-test-detects-residual-disease-and-cancer-recurrence

The investigation clinically validated the OncoK9 test from PetDx, reinforcing previous study results.

12/18/2023

Friends, Just wanted to share Dr. Clifford’s informative piece with you. 🐾

We would be remiss in not mentioning Bellingham Veterinary as they are the only private veterinary hospital in the country, including Veterinary Teaching Hospitals, to offer bone marrow transplantation for the treatment of canine lymphoma. They are truly pioneers in the field of BMT in dogs and have led the way.
If you are so inclined to do so take a peek at some of our adorable pet patients who beat the odds. Makes us so very happy!

https://drive.google.com/file/d/1Xi0JBKGaOVOvS_y5mxADzX3RXpVdpjYY/view?usp=drive_web

Canine lymphoma: new approaches to diagnostics and treatment

Dec 14, 2023
By Shannon Stolz, Senior Editor of Special Projects

“[Phenotyping] provides me information when I see the case and allows me to make more streamlined consult with the owners,” said Craig A. Clifford, DVM, MS, DACVIM (Oncology), at the recent Fetch dvm360 conference in Long Beach, California.1 As the veterinary industry shifts toward more individualized care approaches, canine lymphoma treatments and diagnostics are undergoing notable change. Because the different types of lymphoma have varying survivability rates and respond to treatment differently, the veterinary world is starting to put more focus on the initial prognosis.

Phenotyping
Prior to planning treatment for canine lymphoma, a crucial step is to determine which classification the patient falls into; around one third of dogs are considered to have T-cell lymphoma, while around two thirds are considered to have B-cell lymphoma, and

12/13/2023

An open and wonderfully fun Invitation from Hotel Leo, a home away from home for pet parents who are traveling to Bellingham for Bone Marrow Transplantation at Bellingham Veterinary, Bellingham, Washington. You will receive an amazing discount at a very unique hotel. Please reach out to Brandon Lehmeyer, Complex General Manager
Hotel Leo | Heliotrope Hotel
Hotel Leo d 360.746.9097 | Heliotrope d 360.201.2914
o. office 360-935-4013

Letters to Santa!!! 🎄🎅🎄

Thursday & Saturdays in December
14 | 16 | 21 | 23

Santa! We know him! Stop by Hotel Leo on Thursday and Saturday nights in December to write a letter to Santa sip on complimentary hot cocoa and decorate an ornament. No matter if you have been naughty or nice Santa would love to hear from you. While the little ones write their letters we encourage parents to make their way to Amendment 21 for a special treat of their own – cocktail wine n/a beverages or a snack to share! All letters dropped off to Santa’s mailbox by December 23rd will receive a response from Santa himself!

12/12/2023

Two decades ago, Dr. Chand Khanna, DVM, ACVIM Oncologist, proposed what might have seemed like a radical idea: creating a program at the National Institutes of Health to promote the study of naturally occurring cancer in dogs.

This year, the Comparative Oncology Program within the NCI Center for Cancer Research is celebrating its 20th anniversary. The program features the Comparative Oncology Trials Consortium, a network of academic centers in comparative oncology.

We are incredible honored and forever grateful that Dr. Khanna is Chairman Emeritus of The Perseus Foundation. His support has been incredible.

12/11/2023

Shout out to Trupanion for assisting pet owners by covering T Cell Therapy! With a coverage of 90% reimbursement and immediate payment to clinics, it truly can make a difference as we choose treatments options for our BFF🐾❤️🐾

12/06/2023

In this episode of Beyond the Clinic, you will be listening to the with acclaimed author and Diplomate, Renee Alsarraf DVM, DACVIM (Oncology), as she leads all animal owners through navigating a cancer diagnosis while debunking seven common myths about pet cancer along the way.

Information is powerful against the fight. If you are so inclined, please feel free to share by this episode of Beyond the Clinic with your every single pet owner you know.

In each episode of the VetSpecialists podcast, we invite Board-Certified Veterinary Specialists to sit down with us and discuss relevant topics in veterinary medicine and how they pertain to the general public of animal owners.

12/02/2023

Exciting News 🐾

Merck Animal Health Announces Availability of Novel Canine Oncology Therapy to Veterinary Specialists Practicing Oncology Nationwide

Gilvetmab is Available to Veterinary Specialists Practicing Oncology to Treat Dogs with Mast Cell Tumors and Melanoma

RAHWAY, N.J., Oct. 13, 2023 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that its caninized monoclonal antibody gilvetmab (gil-VET-mab) is now available to veterinary specialists practicing oncology across the United States. Gilvetmab previously received conditional license approval for the treatment of dogs with mast cell tumors and for treatment of dogs with melanoma by the U.S. Department of Agriculture (USDA) Center for Veterinary Biologics (CVB).

Developed exclusively for therapeutic use in dogs, gilvetmab is a checkpoint inhibitor that specifically targets PD-1, reactivating the dog’s immune system to recognize and fight cancer cells. Mast cell tumor is one of the most common types of cancer in dogs comprising 20% of skin cancer cases1, and melanoma accounts for approximately 7% of all malignant tumors in dogs2. During initial trials, gilvetmab resulted in tumor shrinkage or maintenance of stable disease in 73% of dogs with mast cell tumor and 60% of dogs with melanoma over the course of the 20-week trial3.

“As an industry leader with vast research knowledge and scientific expertise in the immunotherapy field, we’re proud to announce the availability of gilvetmab to veterinary oncologists,” said Ian Tarpey, vice president, Research and Development, Merck Animal Health. “This new treatment adds a pioneering innovation to the field of veterinary oncology and elevates our extensive portfolio of veterinary medicines, vaccines, and technology solutions, further demonstrating our ongoing commitment to The Science of Healthier Animals.”

“At Merck Animal Health, we are committed to delivering technology, products and services that help improve the health and wellbeing of animals, including the beloved dogs in our homes,” said Laura Greene, DVM, DACVIM, senior professional services veterinarian and national internal medicine expert, Merck Animal Health. “With the availability of gilvetmab, a first-in-class monoclonal antibody, veterinary specialists practicing oncology now have a new option to treat dogs with mast cell tumor or melanoma. We look forward to working with the veterinary professionals who are pioneering the integration of this novel immunotherapy into their treatment plans.”

As Merck Animal Health enters the emerging field of canine oncology, gilvetmab will be administered by veterinary specialists practicing oncology. For clinics and veterinary professionals looking to learn more information about gilvetmab, please visit Merck Animal Health’s website.

In addition, the Gilvetmab Product Grant Program provides support to veterinary specialists practicing oncology seeking to better understand the role of Merck Animal Health’s conditionally licensed gilvetmab in various clinical scenarios. If you are interested in details on how to participate in ongoing clinical trials involving gilvetmab and dogs with stage III melanoma, please visit Melanoma Archives – Animal Clinical Investigation (animalci.com).

11/28/2023

Peeking Out to remind you: Giving Tuesday is here🥰

https://drive.google.com/file/d/1kAYLHIrF7O645e-bUHfEZqkxOZcpMvlx/view?usp=drivesdk

11/27/2023

From the amazing team at CSU Animal Cancer Center:

ne of the ways we’re fighting cancer and improving outcomes is through clinical trials.

Clinical trials are research studies that help us improve the detection and treatment of illnesses. Our clinical trials program enrolls client-owned pets to evaluate the effectiveness of new drugs, find novel uses of old drugs, or investigate new approaches to surgery and/or radiation therapy to treat cancer.

Many of the standard treatments used today are the result of clinical trials. Clinical trials are important because they –

- Contribute to research that discovers better treatments for pets and people with cancer;
- Provide an alternative when standard treatment options are no longer effective;
- Explore new therapies to treat disease that is unlikely to have a significant response to standard treatment;
- Offer financial assistance

As we bring awareness to pet cancer during National Pet Cancer Awareness Month, we want to spread the word about our clinical trials program. Not only could it mean your pet gets a novel treatment, but being in the study will also help future pets and people fight cancer in the future.